Submit Your Leukemia Research to Leading Experts
Join hematologists and oncologists worldwide advancing leukemia treatment, diagnosis, and patient outcomes
Why Leukemia Researchers Choose Us
Advances in Leukemia provides a specialized platform for hematologists, oncologists, and translational researchers to share breakthrough discoveries in acute and chronic leukemia. Our expert editorial board includes leading clinicians and scientists who understand the complexities of leukemia pathophysiology, molecular genetics, immunotherapy, and precision medicine approaches. Whether you're reporting clinical trial outcomes, novel therapeutic targets, or epidemiological studies, your work will reach the global leukemia research community through comprehensive indexing and immediate open access publication.
Two Convenient Submission Methods
Choose the submission pathway that best fits your workflow. Both methods ensure your manuscript receives the same rigorous peer review by leukemia specialists and hematology experts.
ManuscriptZone Portal
Our comprehensive manuscript management system designed for complex submissions with multiple authors, extensive supplementary materials, and ongoing revisions.
- Auto-save functionality protects your work
- Real-time submission status tracking
- Direct communication with editors and reviewers
- Secure document management
- Revision tracking and version control
- Mobile-responsive interface
Best for: Original research articles, systematic reviews, clinical trials, and manuscripts requiring multiple revision rounds.
Submit via ManuscriptZoneQuick Submission Form
Streamlined submission process for straightforward manuscripts. Complete your submission in minutes without creating an account.
- No registration required
- Simple, intuitive interface
- Fast upload process
- Immediate confirmation
- Perfect for case reports and short communications
- Mobile-friendly design
Best for: Case reports, short communications, letters to the editor, and rapid communications requiring expedited review.
Use Quick Submission FormLeukemia-Specific Article Types We Publish
We welcome diverse contributions that advance understanding of leukemia biology, treatment, and patient care. Each manuscript type undergoes specialized peer review by experts in the relevant subdiscipline.
Original Research Articles
Novel findings in leukemia pathogenesis, molecular mechanisms, therapeutic targets, or clinical outcomes. Include laboratory studies, translational research, and patient cohort analyses.
Clinical Trial Reports
Phase I-IV clinical trial results for leukemia treatments, including novel agents, combination therapies, and treatment protocols. Must follow CONSORT guidelines.
Systematic Reviews & Meta-Analyses
Comprehensive evidence synthesis on leukemia diagnosis, treatment efficacy, prognostic factors, or epidemiology. Must follow PRISMA guidelines.
Case Reports
Unusual presentations, rare leukemia subtypes, unexpected treatment responses, or novel diagnostic challenges. Must provide clinical learning value.
Molecular & Genetic Studies
Research on leukemia genomics, epigenetics, transcriptomics, proteomics, or molecular pathways. Include next-generation sequencing studies and biomarker discovery.
Immunotherapy & Cellular Therapy
Studies on immune-based leukemia treatments including CAR-T cells, checkpoint inhibitors, monoclonal antibodies, and vaccine approaches.
Epidemiological Studies
Population-based research on leukemia incidence, prevalence, risk factors, survival trends, or health disparities. Include registry-based analyses.
Rapid Communications
Time-sensitive findings of immediate importance to the leukemia research community. Fast-tracked review for breakthrough discoveries.
Review Articles
Comprehensive overviews of current knowledge in specific areas of leukemia research, treatment, or clinical management. Invited and unsolicited reviews accepted.
Methodology Papers
Novel techniques, protocols, or analytical methods for leukemia research, diagnosis, or monitoring. Include validation data and reproducibility information.
Translational Research
Studies bridging basic science discoveries and clinical applications in leukemia. Include preclinical studies with clear clinical relevance.
Perspectives & Commentaries
Expert opinions on controversial topics, emerging trends, or future directions in leukemia research and treatment. Typically invited but unsolicited submissions considered.
Pre-Submission Checklist for Leukemia Research
Ensure your manuscript meets these requirements before submission to expedite the review process:
- Manuscript prepared in Word or LaTeX format with line numbering enabled for reviewer convenience
- Title page includes: Full title, all author names and affiliations, corresponding author contact details, word count, and conflict of interest statement
- Structured abstract (250 words max) with Background, Methods, Results, and Conclusions sections for research articles
- Keywords selected from Medical Subject Headings (MeSH) terms for optimal indexing
- Figures prepared at publication quality: TIFF or EPS format, minimum 300 DPI resolution, properly labeled axes and legends
- Tables formatted correctly: Editable format (not images), clear headers, footnotes for abbreviations
- Ethics approval obtained for human subjects research with IRB approval number and informed consent statement
- Clinical trial registration number included for all interventional studies (ClinicalTrials.gov, EudraCT, etc.)
- Patient consent for case reports with signed consent forms for identifiable patient information
- Data availability statement describing how readers can access underlying data (required for all research articles)
- Competing interests declared for all authors, including financial relationships with pharmaceutical companies
- Author contributions specified using CRediT taxonomy (Conceptualization, Methodology, Writing, etc.)
- Funding sources acknowledged with grant numbers and funding agency names
- References formatted according to journal style (Vancouver system, numbered in order of appearance)
- Supplementary materials prepared if applicable (protocols, datasets, additional figures)
Peer Review Timeline: What to Expect
We maintain transparent, predictable timelines while ensuring rigorous peer review by leukemia specialists. Track your manuscript status in real-time through ManuscriptZone.
Submission Received
Your manuscript is logged into our system and you receive immediate confirmation with a unique manuscript ID. Our editorial office performs initial completeness check.
Day 0Editorial Screening
Editor-in-Chief or Associate Editor reviews manuscript for scope fit, scientific merit, and adherence to guidelines. Plagiarism check performed using iThenticate (similarity must be <20% for leukemia research).
Days 1-3Reviewer Assignment
Handling editor selects 2-3 expert reviewers with specific expertise in your research area (e.g., acute myeloid leukemia, CAR-T therapy, molecular genetics). Reviewers are active researchers in leukemia with recent publications.
Days 4-7Peer Review Period
Expert reviewers evaluate scientific rigor, methodology, data interpretation, and clinical relevance. They assess statistical analyses, experimental design, and adherence to reporting guidelines (CONSORT, STROBE, ARRIVE as applicable).
Days 8-21Editorial Decision
Editor synthesizes reviewer comments and makes decision: Accept, Minor Revision, Major Revision, or Reject. You receive detailed feedback with specific recommendations for improvement.
Days 22-28Revision Submission
If revisions requested, you submit revised manuscript with point-by-point response to reviewers. Most authors complete revisions within 30-60 days. We provide guidance on addressing reviewer concerns.
Author timelineRe-Review (if needed)
For major revisions, manuscript returns to original reviewers to verify concerns addressed. Minor revisions reviewed by editor only for faster processing.
Days 29-42Final Acceptance
Once all concerns addressed, manuscript formally accepted. You receive acceptance letter and article processing charge (APC) invoice. Waivers available for eligible authors.
Day 43-50Production & Publication
Professional copyediting, typesetting, and XML conversion. You review and approve final proofs. Article published online with DOI assignment and immediate open access.
Days 51-60Average total timeline: 60 days from submission to publication for manuscripts accepted without major revisions. Rapid communications fast-tracked to 30 days.
Why Leukemia Researchers Trust Us
Comprehensive Indexing
Your research Your research gains worldwide visibility through indexing in Google Scholar, connecting it with the global scientific community.
Expert Peer Review
Manuscripts reviewed by practicing hematologists, leukemia researchers, and clinical oncologists with active research programs and recent publications in your specific area.
Fast Decisions
Average 21 days to first decision. Rapid communications reviewed in 10 days. We respect your time while maintaining rigorous quality standards.
Global Open Access
Immediate worldwide access upon publication. No paywalls, no embargoes. Your research reaches clinicians in resource-limited settings who need it most.
Ethical Publishing
COPE (Committee on Publication Ethics) member. Strict adherence to publication ethics, transparent peer review, and research integrity standards.
APC Waivers Available
Financial support for authors from low- and middle-income countries. Partial waivers for unfunded research. Quality research should not be limited by funding.
Article-Level Metrics
Track your article's impact with downloads, citations, Altmetric scores, and social media mentions. Understand how your research influences the field.
Transparent Process
Clear submission guidelines, predictable timelines, and detailed reviewer feedback. No hidden fees or surprise charges. You know exactly what to expect.
Manuscript Preparation Guidelines for Leukemia Research
Structure Your Manuscript
Follow this structure for original research articles to ensure comprehensive reporting:
- Title: Concise, specific, including leukemia subtype if applicable (e.g., "Novel BCR-ABL1 Inhibitor in Chronic Myeloid Leukemia")
- Abstract: Structured format with Background, Methods, Results, Conclusions (250 words maximum)
- Introduction: Clinical context, knowledge gaps, study rationale, specific objectives
- Methods: Detailed enough for replication - patient selection, diagnostic criteria, treatment protocols, statistical analyses, ethics approval
- Results: Present findings logically, use tables/figures for complex data, report statistical significance with confidence intervals
- Discussion: Interpret findings, compare with existing literature, acknowledge limitations, discuss clinical implications
- Conclusions: Clear take-home messages, avoid overstating findings, suggest future research directions
- References: Vancouver style, numbered in order of appearance, include DOIs when available
Reporting Guidelines
Adhere to discipline-specific reporting standards to ensure transparency and reproducibility:
- Clinical Trials: CONSORT checklist and flow diagram required, trial registration number mandatory
- Observational Studies: STROBE checklist for cohort, case-control, and cross-sectional studies
- Systematic Reviews: PRISMA checklist and flow diagram, protocol registration recommended
- Diagnostic Studies: STARD guidelines for reporting diagnostic accuracy
- Animal Studies: ARRIVE guidelines for reporting in vivo experiments
- Case Reports: CARE guidelines for clinical case reporting
Data Presentation
Present your leukemia research data clearly and professionally:
- Figures: High-resolution (300 DPI minimum), clear labels, color-blind friendly palettes, legends explaining all symbols
- Tables: Self-explanatory, define all abbreviations in footnotes, use consistent formatting
- Statistical Reporting: Report exact p-values, confidence intervals, effect sizes, and statistical tests used
- Survival Curves: Include number at risk, median survival times, hazard ratios with confidence intervals
- Flow Cytometry: Report gating strategies, antibody clones, compensation methods
- Molecular Data: Deposit raw sequencing data in public repositories (GEO, SRA), provide accession numbers
Ready to Share Your Leukemia Research?
Join leading researchers advancing leukemia treatment and patient outcomes. Your work deserves a journal that understands the complexities of hematologic malignancies.
Start your submission today and reach the global leukemia research community.
Submit Your Manuscript NowNeed assistance with your submission? Our editorial team is here to help: [email protected]
